A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 301
- Registration Number
- NCT00672997
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- Open-angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 158
- Registration Number
- NCT00670033
24 Hour IOP Lowering Efficacy of AL-3789
Phase 2
Completed
- Conditions
- Open-angle Glaucoma
- Interventions
- Drug: AL-3789 Sterile Suspension
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-11-29
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 25
- Registration Number
- NCT00643669
- Locations
- 🇺🇸
Inglewood, Inglewood, California, United States
Staining in a Healthy, Non-Dry Eye Population
Completed
- Conditions
- Normal Healthy Eyes
- Interventions
- Other: No intervention required
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 120
- Registration Number
- NCT00643942
- Locations
- 🇺🇸
San Antonio, San Antonio, Texas, United States
Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose Travoprost
Phase 2
Completed
- Conditions
- Ocular HypertensionOpen-angle Glaucoma
- Interventions
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 138
- Registration Number
- NCT00637130
- Locations
- 🇺🇸
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas, United States
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2010-04-12
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 97
- Registration Number
- NCT00631358
- Locations
- 🇨🇦
Waterloo, Waterloo, Canada
🇨🇦Toronto, Toronto, Canada
Adjunctive Study of AL-37807 Ophthalmic Suspension
Phase 2
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: AL-37807 ophthalmic suspension, 0.1%Other: AL-37807 ophthalmic solution vehicle
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 129
- Registration Number
- NCT00620256
- Locations
- 🇺🇸
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas, United States
The Natural History of Geographic Atrophy Progression (GAP) Study
Terminated
- Conditions
- Age-Related Macular DegenerationGeographic Atrophy
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 1000
- Registration Number
- NCT00599846
- Locations
- 🇺🇸
Houston, Houston, Texas, United States
Safety Study of Olopatadine Nasal Spray
Phase 3
Completed
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- Drug: Placebo Nasal Spray
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 890
- Registration Number
- NCT00578331
- Locations
- 🇺🇸
Waco, Waco, Texas, United States
A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates
Phase 2
Terminated
- Conditions
- Corneal Infiltrates
- Interventions
- Drug: Moxifloxacin/dexamethasone phosphate ophthalmic solution
- First Posted Date
- 2007-12-21
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 144
- Registration Number
- NCT00579020
- Locations
- 🇺🇸
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath